News

FDA has approved revisions to the US prescribing information for Amgen’s epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). The decision follows the FDA’s December

Castle Biosciences, a Texas-based cancer diagnostics company, has unveiled DecisionDx-GBM, a molecular brain cancer diagnostic test. It is developed at and licensed from The University of Texas M.

ViRexx has received a contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This 14-month project will focus on the development of bio-nanoparticle-based siRNA

Mylan has received approval from the FDA for its Abbreviated New Drug Application (ANDA), for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg

Angiotech Pharmaceuticals has received approval from the US Food and Drug Administration (FDA), to market its TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System. Its a next-generation drug-eluting stent

Sanofi Pasteur has received an order from the French Ministry of Health to produce a vaccine against the A(H1N1) influenza virus. The company is set to produce initial

Zogenix has got approval from the US FDA for its New Drug Application (NDA) on Sumavel DosePro (sumatriptan injection) needle-free delivery system. It is to treat acute migraine,

Cubist Pharmaceuticals has reported an increase in total sales revenue by 28% for the second quarter of 2009 to $130.8 million, as compared to $101.8 million in the

Tibotec Pharmaceuticals has entered into an agreement with Gilead Sciences for the development and commercialization of a new, once-daily fixed-dose antiretroviral product. It contains Tibotec’s investigational non-nucleoside reverse